Mirabegron + Tolterodine ER

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Overactive Bladder (OAB)

Conditions

Overactive Bladder (OAB)

Trial Timeline

Jul 24, 2014 โ†’ Nov 11, 2015

About Mirabegron + Tolterodine ER

Mirabegron + Tolterodine ER is a approved stage product being developed by Astellas Pharma for Overactive Bladder (OAB). The current trial status is completed. This product is registered under clinical trial identifier NCT02138747. Target conditions include Overactive Bladder (OAB).

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT02138747ApprovedCompleted

Competing Products

20 competing products in Overactive Bladder (OAB)

See all competitors
ProductCompanyStageHype Score
mirabegron + solifenacinAstellas PharmaApproved
85
Mirabegron + PlaceboAstellas PharmaApproved
85
SolifenacinAstellas PharmaApproved
85
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
77
solifenacin succinateAstellas PharmaPhase 3
77
SolifenacinAstellas PharmaPre-clinical
23
BetanisAstellas PharmaPre-clinical
23
SolifenacinAstellas PharmaApproved
85
SolifenacinAstellas PharmaPhase 2
52
mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverineAstellas PharmaPre-clinical
23
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
85
warfarin + YM178Astellas PharmaPhase 1
33
Solifenacin succinateAstellas PharmaPhase 3
77
solifenacin succinate + tolterodineAstellas PharmaPhase 3
77
Mirabegron tablet + Solifenacin tablet + Propiverine tablet + Imidafenacin tablet + Tolterodine capsuleAstellas PharmaApproved
85
Solifenacin succinateAstellas PharmaApproved
85
Mirabegron + PlaceboAstellas PharmaPhase 3
77
SolifenacinAstellas PharmaPre-clinical
23
Solifenacin succinate + TolterodineAstellas PharmaPhase 3
77
Solifenacin succinate + PlaceboAstellas PharmaPhase 3
77